Blueprint Medicines
The Director, US Patient Marketing shapes how the AYVAKIT brand connects with patients and caregivers, translating consumer strategy into branded experiences that drive engagement and long-term brand connection.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2011
Blueprint Medicines is a biotechnology company focused on developing targeted therapies for patients with cancer and rare diseases. The company uses precision medicine and genomics to design drugs that selectively inhibit disease-causing proteins, particularly kinase-driven cancers and systemic mastocytosis.
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
4 days ago
Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
2 weeks ago
Blueprint’s rare disease drug Ayvakit shows long-term benefit
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Blueprint Medicines.
39% above the average for this role
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
Jun 2, 2025
HEME Patient Marketing Associate Director
Vertex
Associate Director, Customer Relationship Management
AstraZeneca
Associate Director, US Max Pipeline
AbbVie
Customer Engagement Manager
State of Indiana
Assistant Manager, Branded Entertainment & Digital Content
General Motors de México
Lead Marketing Strategist
Ferguson Enterprises, LLC